Business segment information (Tables)

9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Schedule of External Net Sales by SBU Reporting Segment

The table below presents external net sales by SBU reporting segment (amounts reported for prior periods have been reclassified to conform to the new segment reporting structure). Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution^®, Trinity ELITE^® and Versashield™ in the Biologics segment.

	External Net Sales by SBU
	Three Months Ended September 30,
(U.S. Dollars, in thousands)	2014		2013		Reported Growth			Constant Currency Growth
			(Restated)
BioStim	$	38,285	$	30,654		25	%		25	%
Biologics		13,856		13,216		5	%		5	%
Extremity Fixation		27,636		24,705		12	%		9	%
Spine Fixation		21,217		23,231		(9	)%		(9	)%
Total Net Sales	$	100,994	$	91,806		10	%		9	%

	External Net Sales by SBU
	Nine Months Ended September 30,
(U.S. Dollars, in thousands)	2014		2013		Reported Growth			Constant Currency Growth
			(Restated)
BioStim	$	114,937	$	105,828		9	%		9	%
Biologics		40,718		39,816		2	%		2	%
Extremity Fixation		82,005		74,112		11	%		9	%
Spine Fixation		64,333		71,969		(11	)%		(11	)%
Total Net Sales	$	301,933	$	291,725		3	%		3	%

Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment

The table below presents net margin, defined as gross profit less sales and marketing expenses, from continuing operations by SBU reporting segment:

	Three Months Ended September 30,						Nine Months Ended September 30,
(U.S. Dollars, in thousands)	2014			2013			2014			2013
				(Restated)						(Restated)
Net margin:
BioStim	$	16,442		$	13,397		$	49,168		$	48,614
Biologics		6,504			6,737			19,500			18,463
Extremity Fixation		8,361			7,089			21,952			17,980
Spine Fixation		3,958			913			11,147			5,796
Corporate		(537	)		(470	)		(1,411	)		(1,376	)
Total net margin		34,728			27,666			100,356			89,477
General and administrative		18,814			12,933			53,643			46,355
Research and development		6,572			6,361			18,818			20,653
Amortization of intangible assets		508			616			1,753			1,725
Costs related to the accounting review and restatement		2,326			2,664			12,959			2,664
Impairment of goodwill		—			19,193			—			19,193
Operating income	$	6,508		$	(14,101	)	$	13,183		$	(1,113	)